Risk factors for community-acquired urinary tract infection caused by fluoroquinolone resistant E. coli;Factores asociados al desarrollo de infección urinaria de origen comunitario causada por Escherichia coli resistente a fluoroquinolonas

Revista Chilena de Infectologia

Volumn 31, Issue 4, 2014, Pages 400-405

  Seija, Verónica ^a   Frantchez, Victoria ^a   Ventura, Verónica ^a   Pintos, Marcos ^a   González, Mariana ^a  

^a Hospital Pasteur Montevideo   (Uruguay)

Author keywords

Antimicrobial resistance; Ciprofoxacin; Urinary tract infection

Indexed keywords

ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; COMMUNITY ACQUIRED INFECTION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HUMAN; MALE; MICROBIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; URINARY TRACT INFECTION; URUGUAY;

ADULT; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; URINARY TRACT INFECTIONS; URUGUAY;

EID: 84923349119     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: 10.4067/S0716-10182014000400004     Document Type: Article

References (38)

1. Litza J A, Brill J R. Urinary tract infections. Prim Care Clin Offce Pract 2010; 37: 491-507.
2. Gupta K, Hooton T M, Naber K G, Wullt B, Colgan R, Miller L G, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52 (5): e103-20.
3. Organización Panamericana de la Salud. Informe Anual de la Red de Monitoreo/ Vigilancia de la Resistencia Antibiótica. Brasilia. 2005.
4. Pedreira W, Anzalone L, Alvez M, Cafferatta A. Fosfomicina trometamol. Una opción terapéutica válida en infecciones urinarias bajas. Rev Med Uruguay 2003; 19: 107-16.
5. Facal J. Infección urinaria. Carta infectológica 2006; 6: 7-12.
6. Ventura V, Seija V, González M, Ventura S, López M, Frantchez V. Prescripción de antibióticos en episodios de infección urinaria comunitaria del adulto. En XV Congreso Panamericano de Infectología, Punta del Este, Uruguay, 7-11 abril, 2011.
7. Andrade S S, Sader H S, Jones R N, Pereira A S, Pignatari A, Gales A C. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines? Mem Inst Oswaldo Cruz 2006; 101: 741-8.
8. Seija V, Frantchez V, Pintos M, Bataglino M N, Torales M, Díaz A, et al. Etiología de la infección urinaria de adquisición comunitaria y perfl de susceptibilidad de Escherichia coli a los principales agentes antimicrobianos. Rev Med Urug 2010; 26: 14-24.
9. Gagliotti C, Buttazzi R, Sforza S, Moro M L, Romagna E. Antibiotic Resistance Study Group. Resistance to fuoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli. J Infect 2008; 57 (3): 179-84.
10. Domingo A D, Cacho J, Coira Nieto A, Lepe Jiménez J A. Diagnóstico microbiológico de las infecciones del tracto urinario. Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. http://www.seimc.org/documentos/protocolos/microbiologia/. (Accedido el 1 de marzo de 2013).
11. Clinical Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement 2007. CLSI document M100-S17.
12. Galas M, Red WHONET Argentina. Grupo KES. Servicio de Antimicrobianos. Instituto Nacional de Enfermedades Infecciosas ANLIS “Dr. Carlos G. Malbrán”. http://antimicrobianos.com.ar/2013/02/boletin-13-grupo-kes/ (accedido el 20 de marzo de 2014).
13. Vásquez G A, Siu H R, Luna E M, Reyes K, Zervos M J. Risk Factors for quinolone-resistant Escherichia coli urinary tract infection. Infect Dis Clin Pract 2009; 17: 309-13.
14. Arslan H, Azap O K, Ergonul O, Timurkaynak F. Risk factors for ciprofoxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005; 56: 914-8.
15. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection 2008; 36: 41-5.
16. Velasco M, Horcajada J P, Mensa J, Moreno-Martínez A, Vila J, Martínez J A, et al. Decreased invasive capacity of quinolone resistant Escherichia coli in urinary tract infection. Clin Infect Dis 2001; 33: 1682-6.
17. Sánchez G V, Master R N, Karlowsky J, Bordon J M. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012; 56: 2181-3.
18. Schito G C, Naber K G, Botto H, Palou J, Mazzei T, Gualco L, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34: 407-13.
19. Kahlmeter G, Poulsen H O. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. Int J Antimicrob Agents 2012; 39: 45-51.
20. Lopardo G, Fridman D, González Arzac M, Calmaggi A, Smayevsky J, Podesta O, et al. Uropathogen resistance: are laboratory-generated data reliable enough? J Chemother 2007; 19: 33-7.
21. Robicsek A, Jacoby G A, Hooper D C. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6: 629-40.
22. Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato N, et al. New plasmid-mediated fuoroquinolone effux pump, QepA, found in an Escherichia coli clinical isolate, Antimicrob. Agents Chemother 2007; 51: 3354-60.
23. Cordeiro N, Robino L, Medina J, Seija V, Bado I, García V, et al. Ciprofoxacin-resistant enterobacteria harboring the aac(6’)-Ib-cr variant isolated from feces of inpatients in an intensive care unit in Uruguay. Antimicrob Agents Chemother 2008; 52: 806-7.
24. Bado I, Robino L, García V, Cordeiro N, Seija V, Gutkind G, et al. First detection of qnr genes in Uruguay. In: 48th Annual ICAAC/ IDSA 46th Annual Meeting, Washington DC, 2008.
25. Levin P D, Fowler R A, Guest C, Sibbald W J, Kiss A, Simor A E. Risk factors associated with resistance to ciprofoxacin in clinical bacterial isolates from intensive care unit patients. Infect Control Hosp Epidemiol 2007; 28: 331-6.
26. Rattanaumpawan P, Tolomeo P, Bilker W B, Fishman N O, Lautenbach E. Risk factors for fuoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections. J Hosp Infect 2010; 76: 324-7.
27. Nicolettia J, Kustera S P, Sulserb T, Zbindenc R, Ruefa C, Ledergerbera B, et al. Risk factors for urinary tract infections due to ciprofoxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland. Swiss Med Wkly 2010; 140: w13059.
28. Blaettler L, Mertz D, Frei R, Elzi L, Widmer F, Battegay M, et al. Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997-2007. Infection 2009; 37: 534-9.
29. Killgore K, March K, Guglielmo J. Risk factors for community-acquired ciprofoxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004; 38: 1148-52.
30. Ena J, Amador C, Martínez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofoxacin resistant Escherichia coli. J Urol 1995; 153: 117-20.
31. Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobial usage and resistance in community acquired Escherichia coli urinary tract infection. J Antimicrob Chemother 2003; 52: 1005-10.
32. Wirtz V J, Dreser A, González R. Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Rev Panam Salud Pública 2010; 27: 219-25.
33. Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, Suetens C, et al. European Surveillance of Antimicrobial Consumption (ESAC) outpatient quinolone use in Europe. J Antimicrob Chemother 2006; 58: 423-7.
34. Ena J, López-Perezagua M M, Martínez-Peinado C, Cia-Barrio MA, Ruíz-López I. Emergence of ciprofoxacin resistance in Escherichia coli isolates after widespread use of fuoroquinolones. Diagn Microbiol Infect Dis 1998; 30: 103-7.
35. Smith S P, Manges A R, Riley L W. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition. Clin Infect Dis 2008; 46: 689-95.
36. Cagnacci S, Gualco L, Debbia E, Schito G C, Marchese A. European emergence of ciprofoxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 2008; 46: 2605-12.
37. Johnson J R, Menard M, Johnston B, Kuskowski M A, Nichol K, Zhanel G G. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother. 2009; 53: 2733-9.
38. Vincent C, Boerlin P, Daignault D, Dozois C M, Dutil L, Galanakis C, et al. Food reservoir for Escherichia coli causing urinary tract infections. Emerg Infect Dis. 2010; 16: 88-95.